Levothyroxine Formulations: Pharmacological and Clinical Implications of Generic Substitution.

Abstract

Oral levothyroxine (LT4) is the standard therapy for patients with hypothyroidism. Oral LT4 is available in several formulations, including tablets, soft gel capsules and oral solution. Multiple brand-name and generic LT4 tablets are available. In the US, the Food and Drug Administration (FDA) has developed a protocol for establishing bioequivalence of LT4 formulations based on serum thyroxine (T4) levels after a single oral dose administered to healthy volunteers. This protocol has been criticized by professional endocrinology associations for using healthy individuals and ignoring serum thyroid-stimulating hormone (TSH) levels. In addition, the protocol did not initially correct for baseline T4 levels, although this was changed in a later version. There are concerns that the FDA's protocol could allow products with clinically significant differences in bioavailability to be declared therapeutically equivalent and interchangeable. Once a generic LT4 has been shown to be bioequivalent to a brand-name LT4, it may be substituted for that brand-name LT4 with no need for dose adjustment or follow-up therapeutic monitoring. Often, the substitution is made by the pharmacy without the physician's knowledge. Even small differences between LT4 formulations can cause significant changes in TSH levels. This may be a particular concern in vulnerable populations, including elderly, pregnant, and pediatric patients. Problems that can be encountered when switching between formulations or when original products are reformulated are discussed in this review. These problems include altered efficacy and adverse events, some of which can be caused by excipients. Patients should be maintained on the same LT4 preparation if possible. If the LT4 preparation is changed, TSH levels should be evaluated and, if necessary, the dose of LT4 adjusted.Funding: Merck.Plain Language Summary: Plain language summary available for this article.

• Authors: Salvatore Benvenga, Allan Carlé
• Journal: Advances in therapy (Adv Ther) Vol. 36 Issue Suppl 2 Pg. 59-71 (09 2019) ISSN: 1865-8652 [Electronic] United States
• PMID: 31485974 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Drugs, Generic
• Thyrotropin
• Thyroxine

Topics

• Biological Availability
• Drug Substitution
• Drugs, Generic (therapeutic use)
• Female
• Humans
• Hypothyroidism (drug therapy)
• Male
• Therapeutic Equivalency
• Thyrotropin (therapeutic use)
• Thyroxine (therapeutic use)
• United States